The second day of the ELPA Educational Training took place on June 23, 2021. After the first day that hosted presentations on Horizon 2020 medical, scientific projects, the second day focused on presentations delivered by pharma companies’ representatives.
The meeting started with Dr. Salvador Augustin, MD from Boehringer Ingelheim, who focused his presentation on Boehringer Ingelheim’s NASH Pipeline Program updates. First, he stressed the unmet needs in NASH treatment and how this is a complex disease. Then, he gave an overview of BI’s upcoming clinical trials in 2021.
After the presentation, a questions and answers session, moderated by Mr Marko Korenjak, ELPA President, allowed the participants to go deeper into details. Attendees were particularly active, and questions were mainly focused on patients’ participation in clinical trials, the lack of information and awareness regarding NASH, and how this topic must channel efforts from all the involved stakeholders.
The second presentation was delivered by Dr. Ed Tucker, MD Chief Medical Officer at Mirum. He gave an overview of Mirum’s commitment to the field of rare liver disease, detailing how they are addressing rare liver diseases for children and adults. He stressed that there are many unmet needs regarding this topic, which is also why patients’organizations are crucial. In conclusion, he showed the participants Mirum’s road to delivering new treatments for rare liver diseases.
Before Mr Marko Korenjak wrapped up the meeting, as it happened after the first presentation, Dr. Tucker’s talk was followed by many questions especially related to clinical trials and ICP in pregnancy.